{"id":"monotherapy-obicetrapib","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated uric acid"},{"rate":null,"effect":"Gout"},{"rate":null,"effect":"Hepatic enzyme elevation"}]},"_chembl":{"chemblId":"CHEMBL6068417","moleculeType":"Small molecule","molecularWeight":"1483.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CETP is a protein that transfers cholesterol esters from HDL to apoB-containing lipoproteins, effectively lowering HDL and raising LDL. By blocking CETP, obicetrapib shifts the lipid profile toward higher HDL and lower LDL cholesterol, potentially reducing cardiovascular risk. This mechanism aims to provide additional lipid-lowering benefit beyond statins in patients with established cardiovascular disease.","oneSentence":"Obicetrapib inhibits CETP (cholesterol ester transfer protein) to increase HDL cholesterol and reduce LDL cholesterol levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:06.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiovascular risk reduction in patients with established coronary heart disease (Phase 3)"}]},"trialDetails":[{"nctId":"NCT07219602","phase":"PHASE3","title":"A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome","status":"RECRUITING","sponsor":"NewAmsterdam Pharma","startDate":"2025-12-11","conditions":"Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)","enrollment":300},{"nctId":"NCT06005597","phase":"PHASE3","title":"Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2024-03-01","conditions":"Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia","enrollment":407},{"nctId":"NCT05266586","phase":"PHASE2","title":"Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2022-03-09","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":119},{"nctId":"NCT04770389","phase":"PHASE2","title":"Randomized Study of Obicetrapib in Combination With Ezetimibe","status":"COMPLETED","sponsor":"NewAmsterdam Pharma","startDate":"2021-02-23","conditions":"Dyslipidemias, High Cholesterol, Hypercholesterolemia","enrollment":112}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CETP inhibitor"],"phase":"phase_3","status":"active","brandName":"Monotherapy obicetrapib","genericName":"Monotherapy obicetrapib","companyName":"NewAmsterdam Pharma","companyId":"newamsterdam-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Obicetrapib is being studied as a potential treatment for lipidemia, type 2 diabetes, metabolic syndrome, dyslipidemias, and high cholesterol. It is being evaluated in combination with ezetimibe or as a standalone treatment in clinical trials.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}